Format

Send to

Choose Destination
Curr Opin Pharmacol. 2007 Dec;7(6):598-604. Epub 2007 Nov 19.

Novel therapeutic approaches in IBS.

Author information

1
UCLA Center for Neurovisceral Sciences & Women's Health, and Departments of Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, CA 90024, USA.

Abstract

Irritable bowel syndrome (IBS) remains an incompletely understood, common syndrome with significant unmet medical needs. Significant progress has been made in the development of novel therapies aimed at normalizing bowel habit alterations and abdominal discomfort, even though some of the most effective treatments are currently only available for patients under a restricted access program from the FDA. Preclinical evidence supports the potential usefulness of several compounds in development for the treatment of chronic abdominal pain. Recent new evidence for a possible role of altered microflora and altered host microbial interactions may provide new treatment targets in the future.

PMID:
18006379
PMCID:
PMC3816523
DOI:
10.1016/j.coph.2007.09.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center